Aardvark Therapeutics, Inc. (AARD)

Key Insights

• Aardvark Therapeutics has entered into an equity distribution agreement with Piper Sandler & Co. to offer and sell up to $150 million of its common stock.
• The company has filed a shelf registration statement on Form S-3 to facilitate the equity offering, indicating potential future capital raising activities.
• The agreement provides Aardvark Therapeutics with additional financial flexibility and the ability to raise funds as needed to support its operations and future growth.